Beatrice Seddon

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Beatrice Seddon, Sandra J. Strauss, Jeremy Whelan et al. · The Lancet Oncology · 2017 · 502 citations · Full text

Guidelines for the Management of Soft Tissue Sarcomas

R. J. Grimer, Ian Judson, D. Peake et al. · Sarcoma · 2010 · 427 citations · Full text

Uterine Sarcomas, Surgical Oncology, British Sarcoma Group +17

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan et al. · Journal of Clinical Oncology · 2015 · 412 citations · Full text

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis

Philippe A. Cassier, Hans Gelderblom, Silvia Stacchiotti et al. · Cancer · 2011 · 258 citations · Full text

Monogenic and polygenic determinants of sarcoma risk: an international genetic study

Mandy L. Ballinger, David L. Goode, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2016 · 210 citations

Epidemiology, Sarcoma Risk, Polygenic Risk +10